Axa
CERE

Axa’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Axa’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-233,680
Closed -$7.43M – 1173
2023
Q2 		$7.43M Buy
233,680
+31,947
+16% +$980K 0.02% 471
2023
Q1 		$4.92M Sell
201,733
-468
-0.2% -$13.7K 0.02% 568
2022
Q4 		$6.38M Buy
202,201
+54,668
+37% +$1.54M 0.02% 529
2022
Q3 		$4.17M Buy
147,533
+22,377
+18% +$666K 0.02% 613
2022
Q2 		$3.31M Sell
125,156
-2,434
-2% -$69.1K 0.01% 675
2022
Q1 		$4.47M Buy
+127,590
New +$3.73M 0.01% 671

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Axa's CERE Position: Q3 2023 in Review

Axa sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2023, closing a stake of 233,680 shares — an estimated $7.43M sold.

Axa first reported a position in CERE in Q1 2022 and held it in 6 quarters. The position peaked at $7.43M in Q2 2023. 119 funds tracked by Wall St. Rank hold CERE as of Q3 2023.

  • Axa reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Axa sold 233,680 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2023, an estimated $7.43M.
  • Axa first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
  • Axa's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $7.43M in Q2 2023.
  • 119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2023.

Based on Axa's 13F filing for Q3 2023, filed 14 Nov 2023.